132 related articles for article (PubMed ID: 8028348)
1. Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma.
Rose PG; Terrien JM; Baker S
J Surg Oncol; 1994 Jul; 56(3):168-71. PubMed ID: 8028348
[TBL] [Abstract][Full Text] [Related]
2. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Sep; 38(3):373-6. PubMed ID: 2227551
[TBL] [Abstract][Full Text] [Related]
3. Tumor markers of epithelial and stromal cell origin at second-look laparotomy in ovarian carcinoma.
Tomás C; Kauppila A
Gynecol Oncol; 1992 Jun; 45(3):279-83. PubMed ID: 1612504
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma.
Meier W; Stieber P; Eiermann W; Schneider A; Fateh-Moghadam A; Hepp H
Gynecol Oncol; 1989 Oct; 35(1):44-6. PubMed ID: 2792900
[TBL] [Abstract][Full Text] [Related]
5. CA 125 surveillance and second-look laparotomy in ovarian carcinoma.
Atack DB; Nisker JA; Allen HH; Tustanoff ER; Levin L
Am J Obstet Gynecol; 1986 Feb; 154(2):287-9. PubMed ID: 3456202
[TBL] [Abstract][Full Text] [Related]
6. Use of CA 125 to monitor patients with ovarian epithelial carcinomas.
Podczaski E; Whitney C; Manetta A; Larson JE; Kirk J; Stevens CW; Lyter J; Mortel R
Gynecol Oncol; 1989 May; 33(2):193-7. PubMed ID: 2703180
[TBL] [Abstract][Full Text] [Related]
7. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
8. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
9. Value of serum 125Ca levels: does the result preclude second look?
Potter ME; Moradi M; To AC; Hatch KD; Shingleton HM
Gynecol Oncol; 1989 May; 33(2):201-3. PubMed ID: 2703182
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of multiple tumor marker assays in second-look procedures for ovarian cancer.
Benedetti Panici P; Scambia G; Baiocchi G; Iacobelli S; Mancuso S
Gynecol Oncol; 1989 Dec; 35(3):286-9. PubMed ID: 2599461
[TBL] [Abstract][Full Text] [Related]
11. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy.
Rose PG; Faulhaber P; Miraldi F; Abdul-Karim FW
Gynecol Oncol; 2001 Jul; 82(1):17-21. PubMed ID: 11426956
[TBL] [Abstract][Full Text] [Related]
12. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Jun; 37(3):319-22. PubMed ID: 2190870
[TBL] [Abstract][Full Text] [Related]
13. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K
Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122
[TBL] [Abstract][Full Text] [Related]
14. Plasma D-dimer measurement as a marker of gynecologic tumors: comparison with Ca 125.
Rella C; Coviello M; De Frenza N; Falco G; Chiuri E; Colavito P; Quaranata M; De Leonardis A
Tumori; 1993 Oct; 79(5):347-51. PubMed ID: 8116080
[TBL] [Abstract][Full Text] [Related]
15. Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation.
Mogensen O; Mogensen B; Jakobsen A; Sell A
Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1835-7. PubMed ID: 3220081
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of second-look laparotomy for patients with epithelial ovarian carcinoma.
Kamura T; Tsukamoto N; Saito T; Kaku T; Matsuyama T; Nakano H
Int J Gynaecol Obstet; 1990 Oct; 33(2):141-7. PubMed ID: 1976547
[TBL] [Abstract][Full Text] [Related]
17. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
Meden H; Rath W; Teichmann A; Kuhn W
Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
[TBL] [Abstract][Full Text] [Related]
18. Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.
Jäger W; Adam R; Wildt L; Lang N
Arch Gynecol Obstet; 1988; 243(2):91-9. PubMed ID: 2456743
[TBL] [Abstract][Full Text] [Related]
19. Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma.
Littell RD; Hallonquist H; Matulonis U; Seiden MV; Berkowitz RS; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):570-4. PubMed ID: 16769104
[TBL] [Abstract][Full Text] [Related]
20. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1992 Jun; 45(3):323-8. PubMed ID: 1612511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
